Hemab Therapeutics
Phase 3Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.
Founded
2019
Focus
AntibodiesBiologics
About
Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.
Funding History
3Total raised: $197M
Series B$135MAccess BiotechnologyJan 15, 2023
Series A$55MNovo HoldingsJan 15, 2021
Seed$7MNovo HoldingsDec 15, 2020
Company Info
TypePrivate
Founded2019
LocationCopenhagen, Denmark
StagePhase 3
Contact
SIMILAR COMPANIES
MipSalus
Pre-clinical · Copenhagen
FluoGuide
Pre-clinical · Copenhagen
Fuse Vectors
Pre-clinical · Copenhagen
Fida Biosystems
Pre-clinical · Copenhagen
CerCell
Pre-clinical · Copenhagen
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile